EVLO (Evelo Biosciences) Short-Term Debt: $33.95 Mil (As of Sep. 2023)


What is Evelo Biosciences Short-Term Debt?

Evelo Biosciences EVLO Short-Term Debt is $33.95 Mil as of Sep. 2023.

Evelo Biosciences's Short-Term Debt for the quarter that ended in Sep. 2023 was $33.95 Mil.

Evelo Biosciences's quarterly Short-Term Debt increased from Mar. 2023 ($43.77 Mil) to Jun. 2023 ($43.92 Mil) but then declined from Jun. 2023 ($43.92 Mil) to Sep. 2023 ($33.95 Mil).

Evelo Biosciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Evelo Biosciences Short-Term Debt Related Terms

Evelo Biosciences Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Evelo Biosciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evelo Biosciences Short-Term Debt Chart

Evelo Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Evelo Biosciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.10 0.00 43.77 43.92 33.95
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $33.95 Mil mean?
Evelo Biosciences (EVLO) has a Short-Term Debt of $33.95 Mil as of Sep. 2023.
Is Evelo Biosciences' Short-Term Debt too high?
Evelo Biosciences' current Short-Term Debt is $33.95 Mil.
How does Evelo Biosciences' Short-Term Debt compare to IMNN and EDSA?
Evelo Biosciences' Short-Term Debt of $33.95 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Evelo Biosciences's current Short-Term Debt is $33.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evelo Biosciences stock overvalued right now?
Evelo Biosciences (EVLO) has a current Short-Term Debt of $33.95 Mil. The current Short-Term Debt is $33.95 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Evelo Biosciences (EVLO), the current Short-Term Debt is $33.95 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evelo Biosciences Business Description

Address 620 Memorial Drive, Cambridge, MA, USA, 02139
Evelo Biosciences Inc is a clinical-stage biotechnology company focused on discovering and developing a new class of oral medicines that act on immune cells in the small intestine with systemic effects. The company is developing EDP1815 as a treatment in psoriasis and atopic dermatitis and EDP2939 in psoriasis.